1. Public Citizen Health Research Group of the Oil, Chemical, and Atomic Workers International Union. Petition to request a zero tolerance for ten carcinogens through an emergency temporary standard issued under the authority of the Occupational Safety and Health Act. December 29, 1972.

2. U.S. Occupational Safety and Health Administration (OSHA). Emergency temporary standard on certain carcinogens. Fed. Reg. 1973;38(85):10929–30.

3. Synthetic Organic Chemical Manufacturers. Association (SOCMA) Benzidine Task Force. Comments on the production and use of benzidine. March 9, 1973.

4. OSHA. Carcinogens. Fed. Reg. 1974;39(20):3756–97.

5. Walker B, Gerber A. Occupational exposure to aromatic amines: Benzidine and benzidine-based dyes. Natl Cancer Inst Monogr. 1981;58:11–13.

6. U.S. National Institute for Occupational Safety and Health (NIOSH). Special occupational hazard review for benzidine-based dyes. 1980. DHHS (NIOSH) publication no. 80–109. Available at: http://www.cdc.gov/niosh/80–109.html. Accessed in June 2007.

7. Ward E, Carpenter A, Markowitz S et al. Excess number of bladder cancers in workers exposed to ortho-toluidine and aniline. J Natl Cancer Inst. 1991;83(7):501– 06.

8. Morigami S, Nisimura I. Experimental studies on aniline bladder tumors. GANN. 1940;34:146–47.

9. Strombeck J. Azotoluene bladder tumors in rats. J Path Bact. 1946;58:275–78.

10. Ekman B, Strombeck J. Demonstration of tumorigenic decomposition products of 2,3 azotoluene. Acta Physiol Scand. 1947;14:43–50.

11. Hartwell JL, ed. Survey of Compounds Which Have Been Tested for Carcinogenic Activity. 2nd ed. Washington, DC: U.S. Public Health
Service publication no. 149, 1951: 88.

12. Foulger JH (director, Medical Research). Letter to Rice RM (executive director, Medical Research, Lilly Research Laboratories, Eli Lilly and Co.). September 15, 1958.

13. Zapp Jr. JA. Deposition in U.S. District Court for the Northern District of Texas, Dallas Division, in the matter of Dorothy Schiro et al. v. E. I. Du Pont de Nemours. Civil action no. 3–85– 0339-T. Scottsdale, AZ: March 2, 1987: 69–71.

14. Cousett J (Association of British Chemical Manufacturer). Letter to Mates E (National Aniline Division, Allied Chemical and Dye Corporation). Re: A.B.C.M. papilloma research scheme. October 11, 1954. Available at http://www.defendingscience.org/upload/ABCM_1954.pdf. Accessed in December 2007.

15. Ferber KH (superintendent, Tests and Inspection Department, Buffalo Plant, Allied Chemical Corporation). Letter to Rahall VH (safety coordinator, New York Office, Allied Chemical Corporation). Subject: MCA safety data sheet: Toluidine. November 25, 1958. Available at http://www.defendingscience.org/upload/Allied_1958.pdf. Accessed in December 2007.

16. Manufacturing Chemists Association (MCA). Officers, board of directors, committees, members. September 1961. Available at http://www.defendingscience.org/upload/MCA_Officers.pdf. Accessed in December 2007.

17. Stephenson FG (secretary, General Safety Committee, Manufacturing Chemists Association, Inc.). Letter to Fleming GG, Kelly RE, Ferber KH, Gois HH (Celanese Corporation of America, Monsanto Chemical Company, National Aniline Division–Allied Chemical Corporation, and American Cyanamid Corporation, respectively). Enclosure: Galley proof for proposed chemical safety data sheet on toluidine. February 24, 1961. Available at http://www.defendingscience.org/upload/MCA_1961.pdf. Accessed in December 2007.

18. Case RA, Pearson JT. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Part 2: Further consideration of the role of aniline and of the manufacture of auramine and magenta (fuchsine) as possible causative agents. Br J Ind Med. 1954;11(3):213–16.

19. Scott TS. Carcinogenic and Chronic Toxic Hazards of Aromatic Amines. New York: Elsevier, 1962.

20. Borneff J. Carcinoma of the bladder found in workers employed in tar distilleries. Zentralblatt fur Arbeitsmedizin und Arbeitsschutz. 1965;15:288–92.

21. Khlebnikova M, Gladkova Y, Kurenko L et al. Problems of labor hygiene and the state of health of workers in the production of o-toluidine. Published and translated to English by the Institute of Idustrial Hygiene and Occupational Diseases, 1971.

22. Rubino GF, Scansetti G, Piolatto G et al. The carcinogenic effect of aromatic amines: An epidemiological study on the role of o-toluidine and 4,40-methylene bis (2-methylaniline) in inducing bladder cancer in man. Environ Res. 1982;27(2):241–54.

23. Genin VA, Pliss GB, Pylev LN et al. Prevention of occupational bladder tumors in toluidine manufacture. Gig Tr Prof Zabol. 1978;7:10–14.

24. Ferber KH (superintendent, Tests and Inspection Department, Buffalo Plant, Allied Chemical Corporation). Memorandum to Daly JF (plant manager, Buffalo plant, Allied Chemical Corporation.) Subject: Biochemical research: Product toxicity ortho toluidine. August 2, 1962.

25. Neeld Jr. WE (director, Medical Division, E. I. Du Pont de Nemours and Co.). Chemical cyanosis cases from Ortho-toluidine. August 18, 1975.

26. Homburger F, Friedell G, Weisburger E et al. Carcinogenicity of simple aromatic amine derivatives in mice and rats [abstract]. Toxicol Appl Pharmacol. 1972;22:280–81.

27. Russfield A, Homburger F, Weisburger J et al. Further studies on carcinogenicity of environmental chemicals including simple aromatic amines [abstract]. Toxicol Appl Pharmacol. 1973;25:446–47.

28. U.S. National Cancer Institute (NCI). Bioassay of o-toluidine hydrochloride for possible carcinogenicity. National Institutes of Health. 1979. DHEW publication no. (NIH) 79–1709.

29. International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans, Vol. 27: Some Aromatic Amines, Anthraquinones and Nitroso Compounds, and Inorganic Fluorides used in Drinking-water and Dental Preparations. April 1982.

30. Hunt NJ (Haskell Laboratory for Toxicology and Industrial Medicine, Central Research Department, E. I. Du Pont de Nemours and Co.). Letter to Schultz EF (product manager, Intermediate Sales, Organic Chemicals Department, E. I. Du Pont de Nemours and Co.). Subject: Ortho-toluidine carcinogenicity. June 12, 1974.

31. Schultz EF (technical manager, Intermediates Division, Organic Chemicals Department, Dyes and Chemicals Division, E. I. Du Pont de Nemours and Co.). Letter to LeCain R (manager, Purchases, Goodyear Tire and Rubber Co.). January 12, 1977.

32. McKusick BC (assistant director, Haskell Laboratory for Toxicology and Industrial Medicine, Central Research and Development Department, E. I. Du Pont de Nemours and Co.). Letter to Finklea JF (director, NIOSH). January 12, 1977.

33. Freudenthal RI, Stephens E, Anderson DP. Determining the potential of aromatic amines to induce cancer of the urinary bladder. Int J Toxicol. 1999;15:353–59.

34. Freudenthal RI, Anderson DP. Re: Monitoring of aromatic amine exposures in workers at a chemical plant with known bladder cancer excess. J Natl Cancer Inst. 1997;89(10):734; author reply 735–36.

35. Freudenthal RI, Anderson DP. A reexamination of recent publications suggesting o-toluidine may be a human bladder carcinogen. Regul Toxicol Pharmacol. 1995;21:199–202.

36. Tannenbaum SR. Bladder cancer in workers exposed to aniline. J Natl Cancer Inst. 1991;83(20):1507; author reply 1507–8.

37. Stephens ER. Re: Monitoring of aromatic amine exposures in workers at a chemical plant with a known bladder cancer excess. J Natl Cancer Inst. 1997;89(10):734–35; author reply 735–36.

38. Ferber KH. Examination before trial in the matter of Sullivan v. E. I. Du Pont de Nemours and Co., Inc., in the U.S. District Court for the Eastern District of Texas, Beaumont Division. Transcript prepared by Jack W. Hunt and Associates, Inc., p. 30. October 27, 1989.

39. NIOSH Alert: Request for assistance in preventing bladder cancer from exposure to o-toluidine and aniline. December 1990. Publication no. DHHS (NIOSH) 90–116.

40. DuPont. Material safety data sheet no. DU000271: O-toluidine. Revision date: October 4, 1990.

41. Vogler W. Confidential Du Pont memorandum to be filed, re: AA-9737 [thirty-four-year-old employee with bladder tumor]. July 10, 1990.

42. Weiss RJ. Email to Fayerweather WE and Karns E. October 25, 1991.

43. Murray W. Affidavit concerning 3,30-dichlorobenzidine (May 15, 1973). Submitted to OSHA’s Standards Advisory Committee on Carcinogens, by Morgan DL (Cleary, Gottlieb, Steen, and Hamilton), June 26, 1973.

44. Ouellet-Hellstrom R, Rench JD. Bladder cancer incidence in arylamine workers. J Occup Environ Med. 1996;38(12):1239–47.

45. Schweiger KE. Testimony of the National Association of Manufacturers on the Emergency Temporary Standard for Certain Carcinogens 29-CFR 1910.93C as revised on July 27, 1973, before a Department of Labor Hearing Officer. September 12, 1973. OSHA Docket H-003, Exhibit no. 24.

46. Korbitz B. Affidavit on OSHA’s proposed standard on 4,40-methylenebis (2-chloroaniline). March 10, 1975. Submitted to OSHA Docket OSH-70 on behalf of the Polyurethane Manufacturers Association by Wahl EJ (Michael, Best, and Friedrich).

47. Ward E, Halperin W, Thun M et al. Bladder tumors in two young males occupationally exposed to MBOCA. Am J Ind Med. 1988;14(3):267–72.

48. Ward E, Halperin W, Thun M et al. Screening workers exposed to 4,4'-methylenebis (2-chloroaniline) for bladder cancer by cystoscopy. J Occup Med. 1990;32(9):865–68.

49. Dietrich H, Dietrich B. Ludwig Rehn (1849–1930): Pioneering findings on the aetiology of bladder cancers. World J Urol. 2000;19:151–53.

50. International Labour Organization. Cancer of the bladder among workers in aniline factories. February 1921. Studies and Reports Series F, no. 1.

51. Xue-Yun Y, Ji-Gang C, Yong-Ning H. Studies on the relation between bladder cancer and benzidine or its derived dyes in Shanghai. Br J Ind Med. 1990;47(8):544–52.

52. Bi W, Hayes RB, Feng P et al. Mortality and incidence of bladder cancer in benzidine-exposed workers in China. Am J Ind Med. 1992;21(4):481–89.

53. Samuels SW. The International Context of Carcinogen Regulation: Benzidine. Banbury Report, vol. 9, 497–512. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1981.